Chroma Medicine
Epigenetic editing company, therapy based on epigenetics
Chroma Medicine is pioneering a new class of genomic medicines that harness epigenetics, nature’s innate mechanism for gene regulation, revolutionizing the treatment of genetically driven diseases.
The epigenome is nature’s gatekeeper for gene expression, governing cell phenotype and function by precisely controlling gene activity without changing the underlying DNA sequence. Building on groundbreaking research from the world’s foremost genomic medicine experts, Chroma Medicine is working at the cutting edge of precision genomics, building an entirely new class of therapeutics to achieve unparalleled control of gene expression.
Visit website: https://chromamedicine.com/
Details last updated 01-Jul-2022
Mentioned in this Resource
Jonathan Weissman
Professor at University of California San Francisco and Investigator at Howard Hughes Medical Institute
Other people at Chroma Medicine
Chroma Medicine News
Chroma secures new investment of 135M for Series B in genetic medicines
Biospace - 01-Mar-2023
Epigenetic medicine approach avoids the pitfalls of traditional CRISPR method of gene editing
Read more...Epigenome editing - technology safer and reversible than CRISPR
Science - 01-Jun-2022
Leaves DNA sequence unaltered while retaining the ability to specifically home
Read more...